Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome

被引:32
|
作者
Obi, Yoshitsugu [1 ,3 ]
Kim, Taehee [1 ,3 ,6 ]
Kovesdy, Csaba P. [4 ]
Amin, Alpesh N. [2 ]
Kalantar-Zadeh, Kamyar [1 ,3 ,5 ]
机构
[1] Univ Calif Irvine, Div Nephrol & Hypertens, Orange, CA 92868 USA
[2] Univ Calif Irvine, Dept Med, Orange, CA 92868 USA
[3] Harold Simmons Ctr Kidney Dis Res & Epidemiol, Orange, CA USA
[4] Univ Tennessee, Div Nephrol, Hlth Sci Ctr, Memphis, TN USA
[5] VA Long Beach Hlth Care Syst, Dept Med, Long Beach, CA USA
[6] Inje Univ, Dept Med, Busan, South Korea
关键词
Cardiorenal syndrome; Chronic kidney disease; Heart failure; Acute kidney injury; Dobutamine; Ultrafiltration; DECOMPENSATED HEART-FAILURE; RENAL-REPLACEMENT THERAPY; ACUTE KIDNEY INJURY; CRITICALLY-ILL PATIENTS; LOW-DOSE NESIRITIDE; VASOPRESSIN ANTAGONIST; INTRAVENOUS DIURETICS; HOSPITALIZED-PATIENTS; TASK-FORCE; LEVOSIMENDAN;
D O I
10.1159/000441283
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cardiorenal syndrome (CRS) encompasses conditions in which cardiac and renal disorders co-exist and are pathophysiologically related. The newest classification of CRS into seven etiologically and clinically distinct types for direct patient management purposes includes hemodynamic, uremic, vascular, neurohumoral, anemia- and/or iron metabolism-related, mineral metabolism-related and protein-energy wasting-related CRS. This classification also emphasizes the pathophysiologic pathways. The leading CRS category remains hemodynamic CRS, which is the most commonly encountered type in patient care settings and in which acute or chronic heart failure leads to renal impairment. Summary: This review focuses on selected therapeutic strategies for the clinical management of hemodynamic CRS. This is often characterized by an exceptionally high ratio of serum urea to creatinine concentrations. Loop diuretics, positive inotropic agents including dopamine and dobutamine, vasopressin antagonists including vasopressin receptor antagonists such as tolvaptan, nesiritide and angiotensin-neprilysin inhibitors are among the pharmacologic agents used. Additional therapies include ultrafiltration (UF) via hemofiltration or dialysis. The beneficial versus unfavorable effects of these therapies on cardiac decongestion versus renal blood flow may act in opposite directions. Some of the most interesting options for the outpatient setting that deserve revisiting include portable continuous dobutamine infusion, peritoneal dialysis and outpatient UF via hemodialysis or hemofiltration. Key Messages: The new clinically oriented CRS classification system is helpful in identifying therapeutic targets and offers a systematic approach to an optimal management algorithm with better understanding of etiologies. Most interventions including UF have not shown a favorable impact on outcomes. Outpatient portable dobutamine infusion is underutilized and not well studied. Revisiting traditional and novel strategies for outpatient management of CRS warrants clinical trials. (C) 2015 S. Karger AG, Basel
引用
收藏
页码:83 / 98
页数:16
相关论文
共 50 条
  • [11] Pathogenesis and therapeutic implications of cardiorenal syndrome
    Nitta, Kosaku
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2011, 15 (02) : 187 - 194
  • [12] Novel therapeutic targets for cardiorenal syndrome
    Trivedi, Mansi Vinodkumar
    Jadhav, Hemant R.
    Gaikwad, Anil Bhanudas
    DRUG DISCOVERY TODAY, 2025, 30 (01)
  • [13] Therapeutic Strategies for Heart Failure in Cardiorenal Syndromes
    House, Andrew A.
    Haapio, Mikko
    Lassus, Johan
    Bellomo, Rinaldo
    Ronco, Claudio
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 56 (04) : 759 - 773
  • [14] The Hemodynamic and Nonhemodynamic Crosstalk in Cardiorenal Syndrome Type 1
    Virzi, Grazia Maria
    Clementi, Anna
    Brocca, Alessandra
    de Cal, Massimo
    Vescovo, Giorgio
    Granata, Antonio
    Ronco, Claudio
    CARDIORENAL MEDICINE, 2014, 4 (02) : 103 - 112
  • [15] Evolving treatment strategies for management of cardiorenal syndrome
    Dandamudi S.
    Chen H.H.
    Current Treatment Options in Cardiovascular Medicine, 2011, 13 (6) : 556 - 569
  • [16] Cardiorenal syndrome—current understanding and future perspectives
    Branko Braam
    Jaap A. Joles
    Amir H. Danishwar
    Carlo A. Gaillard
    Nature Reviews Nephrology, 2014, 10 : 48 - 55
  • [17] Cardiorenal syndrome: review of our current understanding
    Hadjiphilippou, Savvas
    Kon, Sui Phin
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2016, 109 (01) : 12 - 17
  • [18] Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia
    Lavin, Martin F.
    Gueven, Nuri
    Bottle, Stephen
    Gatti, Richard A.
    BRITISH MEDICAL BULLETIN, 2007, 81-82 : 129 - 147
  • [19] Cardiorenal anemic syndrome: clinical significance and therapeutic principles
    Kozlovskaya, LV
    Milovanov, YS
    Fomin, VV
    Milovanova, LY
    TERAPEVTICHESKII ARKHIV, 2005, 77 (06) : 82 - 87